Scientists probe cancer cell metabolism to unlock secrets of drug resistance
NCT ID NCT07189117
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how metabolism in cancer and immune cells influences the bone marrow environment and treatment resistance in blood cancers like leukemia and myelofibrosis. Researchers will analyze samples from 350 participants to measure metabolites, lipids, and gene activity. No new treatment is being tested; the goal is to gather knowledge that could guide future therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could reveal new targets for future treatments that overcome therapy resistance in blood cancers.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly benefit participants and may not lead to new therapies for years, if at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can specially trained immune cells flush out hidden HIV?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a Dual-Action pill tame bone marrow tumors?
- Can a modified enzyme starve Hard-to-Treat blood cancers?